Fig 1.TIF (876.04 kB)
Time flow of the different experimental settings.
figure
posted on 2016-10-20, 17:59 authored by Felix Ulbrich, Kai B. Kaufmann, Alexander Meske, Wolf A. Lagrèze, Michael Augustynik, Hartmut Buerkle, Carlos C. Ramao, Julia Biermann, Ulrich GoebelFirst row: Fluorogold (FG) labeling seven days prior to IRI, subsequent treatment with or without p38 inhibitor (SB203580) and/or iALF-186/ALF-186 and enucleation another seven days later, giving FG the chance to promote into RGC via axonal transport. Second row: IRI with or without p38 inhibitor (SB203580) and/or iALF-186/ALF-186 treatment and enucleation 24 or 48 hours after IRI for molecular analysis. Third row: IRI with or without p38 inhibitor (SB203580) and/or iALF-186/ALF-186 treatment and enucleation 24 or 48 hours after IRI for immunohistochemical analysis.
History
Usage metrics
Categories
Keywords
p 38 MAPKCORM ALF -186 Mediates Anti-Apoptotic Signalingcarbon monoxideRetinal Ganglion Cells Purpose IschemiaJNKRGCanti-apoptotic Bcl -2. InhibitionALF -186 treatment differentiallyResults ALF -186ALF -186mitogen-activated protein kinasesMAPK p 38. CORMsSBtissue damageERKALF -186 treatmentIRI38-MAPK
